Improve the results of phase II trials of thromboprophylaxis with the new oral anticoagulant drugs

Editorial Focus on: Weitz et al. Thromb Haemost 2010; 104: 1150-1157.

• References

• 1 Weitz J. A dose-finding study with TAK-442. Thromb Haemost 2010; 104: 1150-1157.
• 2 Rosencher N, Zufferey P, Samama C. Definition of major bleeding in surgery: an anesthesiologist’s point of view: a rebuttal. J Thromb Haemost 2010; 8: 1442-1443.
• 3 Samama CM, Albaladejo P, Benhamou D. et al. Venous thromboembolism prevention in surgery and obstetrics: clinical practice guidelines. Eur J Anaesthesiol 2006; 23: 95-116.
• 4 Geerts WH, Bergqvist D, Pineo GF. et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 381S-453S.
• 5 Turpie AG, Gallus AS, Hoek JA. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001; 344: 619-625.
• 6 Lassen MR, Dahl OE, Mismetti P. et al. AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery-TREK: a dose-ranging study. J Thromb Haemost 2009; 7: 566-572.
• 7 Eriksson BI, Borris LC, Dahl OE. et al. Dose-escalation study of rivaroxaban (BAY 59–7939) – an oral, direct Factor Xa inhibitor- for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res 2007; 120: 685-693.
• 8 Fisher WD, Eriksson BI, Bauer KA. et al. Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies. Thromb Haemost 2007; 97: 931-937.
• 9 Eriksson BI, Borris LC, Dahl OE. et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59–7939), for thromboprophylaxis after total hip replacement. Circulation 2006; 114: 2374-2381.
• 10 Eriksson BI, Dahl OE, Büller HR. et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005; 3: 103-111.
• 11 Leil TA, Feng Y, Zhang L. et al. Quantification of apixaban’s therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose. Clin Pharmacol Ther 2010; 88: 375-382.
• 12 Eriksson BI, Dahl OE, Rosencher N. et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-956.
• 13 Eriksson BI, Dahl OE, Rosencher N. et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5: 2178-2185.
• 14 Lassen MR, Raskob GE, Gallus A. et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375: 807-815.
• 15 Delavenne X, Zufferey P, Baylot D. et al. Population pharmacokinetics of fondaparinux administered at prophylactic doses after major orthopaedic surgery in everyday practice. Thromb Haemost 2010; 104: 252-260.
• 16 Strebel N, Prins M, Agnelli G. et al. Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery?. Arch Intern Med 2002; 162: 1451-1456.
• 17 Turpie A, Bauer K, Eriksson B. et al. Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration. Thromb Haemost 2003; 90: 364-366.
• 18 Zufferey P, Laporte S, Molliex S. et al. Ximelagatran and melagatran vs. low-molecular-weight heparin in major orthopedic surgery: relationship between efficacy and safety and timing of initial administration. J Thromb Haemost 2005; 3: 1104-1107.
• 19 Ginsberg JS, Davidson BL, Comp PC. et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009; 24: 1-9.
• 20 Lee A, Agnelli G, Büller H. et al. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 2001; 104: 74-78.
• 21 Laux V, Perzborn E, Heitmeier S. et al. Direct inhibitors of coagulation proteins – the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?. Thromb Haemost 2009; 102: 892-899.
• 22 Wolowacz SE, Roskell NS, Plumb JM. et al. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost 2009; 101: 77-85.
• 23 Deinum J, Mattsson C, Inghardt T. et al. Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637. Thromb Haemost 2009; 101: 1051-1059.
• 24 Mueck W, Borris LC, Dahl OE. et al. Population pharmacokinetics and pharmacodynamics of once-and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008; 100: 453-461.
• 25 Turpie AG, Bauer KA, Davidson BL. et al. EXPERT Study Group.. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost 2009; 101: 68-76.